PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients
Abstract
Authors
R. Mesa S. Hudgens L. Floden J. Palmer V. Gupta D.P. McLornan M.F. McMullin J.J. Kiladjian L. Foltz U. Platzbecker M.L. Fox A.J. Mead D.M. Ross S.T. Oh A. Perkins M.F. Leahy S. Deheshi R. Donahue B.J. Klencke S. Verstovsek